Despite this great success, many preclinical and clinical studies suggest that congenital and acquired resistance to anti-PD1 treatment frequently occurs, resulting in tumor relapse and treatment failure in HCC patients [6]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.